All 1 tracked stories fall under one category: pharma. Kaltura, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 4 original sources each against 2.6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Lomecel-B
All 1 tracked stories fall under one category: pharma. Kaltura, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 4 original sources each against 2.6 for the same window. At 5, the average consequence score sits below the same-window beat average of 6. We currently track 1 Biotech story that mention Lomecel-B, all published on March 19, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Lomecel-B. Shared-story counts are live from our verified record — not editorial picks.
Longeveron Inc. (LGVN) reported Q4 2025 results, highlighting clinical advancements in its Lomecel-B cell therapy for rare pediatric heart conditions and Alzheimer's disease. Despite clinical momentum, the company is managing significant financial headwinds, including a recent NASDAQ compliance notice and a subsequent capital raise in March 2026.
Lomecel-B is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.